Skip to search formSkip to main contentSkip to account menu

MM-141

Known as: Anti-ErbB3/Anti-IGF-1R Bispecific Monoclonal Antibody MM-141 
A bispecific monoclonal antibody directed against the human epidermal growth factor receptor ErbB3 (Her3) and the human insulin-like growth factor-1… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Antibodies, Bispecific
NCIt Antineoplastic Agent Terminology

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A phase 1 biomarker-directed multi-arm study evaluating the co-administration of MM-151 with MM-121, MM-141, or trametinib in EGFR-driven cancers.
TPS11619Background: The Epidermal Growth Factor Receptor (EGFR) is a key driver of tumor growth in colorectal cancer (CRC… 
2016
2016
Abstract 1209: Istiratumab (MM-141), a bispecific antibody targeting IGF-1R and ErbB3, inhibits pro-survival signaling in vitro and potentiates the activity of standard of care chemotherapy in vivo…
Insulin-like growth factor receptor 1 (IGF-1R) signaling has been implicated in the pathogenesis of ovarian cancer. However… 
2016
2016
Abstract 1199: A network biology screen reveals ligand-receptor pathway connections and resistance mechanisms to RTK-directed therapies in cancer cells
Purpose: Although there are many well-defined signaling pathways in tumor cells that provide druggable targets, emergence of… 
2015
2015
Abstract CT237: Preclinical characterization and first-in-human study of MM-141, a dual antibody inhibitor of IGF-1R and ErbB3
Background: MM-141 is a tetravalent bi-specific monoclonal antibody that binds IGF-1R and ErbB3, oncogenic receptors commonly co… 
2014
2014
First-in-human study of MM-141: A novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3.
384 Background: MM-141 is a novel tetravalent bispecific monoclonal antibody that binds IGF-1R and ErbB3 and blocks both ligand… 
2013
2013
Rapid optimization and prototyping for therapeutic antibody-like molecules
Multispecific antibody-like molecules have the potential to advance the standard-of-care in many human diseases. The design of… 
2013
2013
Abstract 2077A: MM141, a novel bispecific antibody co-inhibitor of IGF-1R and ErbB3, inhibits the proliferation of melanoma cells.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Identification of druggable targets along with new… 
2012
2012
Abstract 2719: MM-141, a novel bispecific antibody co-targeting IGF-1R and ErbB3, blocks ligand-induced signaling and demonstrates antitumor activity
2012
2012
Abstract A38: MM-141, a novel tetravalent bispecific antibody directed at IGF-1R and ErbB3 that inhibits pancreatic tumor cell growth and potentiates the effects of gemcitabine.
Purpose: Overall 5-year survival rates for patients diagnosed with pancreatic cancer is approximately 5.5% and most patients do… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)